Loading...
Solid Tumours2020-11-30T16:49:34+01:00

ESMO 2020 Solid Tumours – virtual

Milestones of PD-1 inhibition in gastric and esophageal cancer

Milestones of PD-1 inhibition in gastric and esophageal cancer Gastric cancer, gastroesophageal junction (GEJ) adenocarcinoma, and esophageal adenocarcinoma are substantial causes of cancer-related mortality worldwide and have poor 5-year overall survival (OS) when diagnosed at an advanced stage [1, 2].

Getting innovation from the laboratories into clinical practice

Getting innovation from the laboratories into clinical practice Andrés Cervantes, MD, PhD, Department of Medical Oncology, Hospital Clinic Universitario, Biomedical Research institute INCLIVA, University of Valencia, Spain Which data presented at ESMO 2020 in the field of gastric cancer, gastro­eso­phageal junction adeno­carcinoma and esophageal cancer do you deem practice-changing? The ESMO congress has provided amazing new data on gastroesophageal cancer, and great contributions by

Ovarian cancer: taking PARP inhibition one step further

Ovarian cancer: taking PARP inhibition one step further Individualized dosing of niraparib Niraparib has been approved as maintenance treatment for patients with plat­inum-sensitive recurrent ovarian cancer (OC) based on the results of the NOVA trial [1]. The starting dose used in NOVA was 300 mg orally daily.

Novel combination approaches in various solid tumors

Novel combination approaches in various solid tumors Lenvatinib plus pembrolizumab The anti-angiogenic multikinase in­hibitor lenvatinib has been shown to ­exert immunomodulatory effects that enhance the anti-tumor activity of anti-PD-1 antibodies [1]. In the early-phase setting, lenvatinib plus pembrolizumab induced partial responses in patients with different tumor types [2].

DOWNLOADS

All downloads from ESMO 2020

ESMO Solid Tumours 2020 cover

Slide Kit Pd-1/PD-L1 and PARP inhibition on GI and ovarian cancers

ESMO 2020 Solid Tumours English

Coming soon full report (english)

ESMO 2020 Solid Tumours Mandarin

Comming sonn full report (mandarin)

EXPERT VIDEOS

All videointerviews from ESMO Solid Tumours 2020

Andrés Cervantes talks about novel findings obtained in the field of gastric cancer, gastroesophageal junction adenocarcinoma and esophageal cancer as well as developments in hepatocellular carcinoma and investigational immunotherapies that might evolve into new treatment approaches.

Eric Van Cutsem gives an overview of practice-changing results obtained for gastrointestinal cancers including colorectal cancer, gastric cancer and esophageal cancer and describes progress that has recently been made with respect to certain biomarkers.

The ESMO congress has provided amazing new data on gastroesophageal cancer, and great contributions by different authors all over the world have been presented. Patients with advanced gastric cancer used to have a median overall survival of less than 1 year when treated with conventional chemo­therapy. For the first time, this was prolonged to more than 1 year due to the ­addition of checkpoint inhibition.

Andrés Cervantes • MD • PhD, Department of Medical Oncology, Hospital Clinic Universitario, Biomedical Research institute INCLIVA, University of Valencia, Spain

ESMO 2019 – Congress digest advanced Solid Tumours – Barcelona

Lecture Board: Hendrik-Tobias Arkenau, MD, PhD; Nicoletta Colombo, MD; Pascal Hammel, MD; Maha Hussain, MD; Paolo Nuciforo, MD, PhD; Bertrand Routy, MD, PhD; Gert Schachtner, MD; Christian Schauer, MD; Agostina Stradella, MD
Medical Writer: Dr. Judith Moser

Preface

Preface Dear readers, With “memo inOncology” Springer has created a medical education platform that is globally accessible and offers value to health care professionals in oncology (www.memoinoncology.com).

New applications of PARP inhibitors

New applications of PARP inhibitors Metastatic castration-resistant prostate cancer Metastatic castration-resistant prostate cancer (mCRPC) that progresses after androgen-receptor(AR)–targeted therapy (i.e., enzalutamide or abiraterone) and taxane-based chemotherapy is associated with a poor prognosis [1].

Increasing PARP inhibitor activity via several mechanisms of action

Increasing PARP inhibitor activity via several mechanisms of action Hendrik-Tobias Arkenau, MD, PhD, FRCP, Sarah Cannon Research Institute, London, UK What is your take-home message from ESMO 2019 in relation to the use of PARP inhibitors in solid tumors? Several studies showing favorable results with PARP inhibitors have been reported at this year’s ESMO Congress. In particular, the results of the PAOLA study can be considered a major breakthrough [1].

序言

序言 亲爱的读者们, 借助“memo inOncology”,施普林格创建了一个能够全球访问的医学教育平台,向肿瘤学领域的医疗保健专业人士提供有价值的内容(www.memoinoncology. com)。在过去的四年中,我们报道了ASCO、ESMO、WCLC、ELCC或ESMO Asia等重大会议在肺癌领域的最新内容荟萃。我们的大会报告及其中文和日文译本在国际上受到了极大关注。因此,我们决定在该成功的基础上进行积极扩充,创建有关其他实体瘤的更多内容。本期内容涵盖有关抗PD-1治疗的新型

胃癌和食管癌、肝细胞癌以及尿路上皮癌中的PD-1抑制

胃癌和食管癌、肝细胞癌以及尿路上皮癌中的PD-1抑制 胃癌和食管癌 胃和胃食管交界处(GEJ)发生的腺癌在全球最常见的恶性肿瘤中排名第五[1, 2],在男性和女性中均为癌症相关死亡的第三大主要原因[3]。由于该疾病无早期症状的特征,因此大多数患者在晚期才得以诊断。尽管全球发病率下降且治疗取得显著进展,仍需进一步努力来改善预后[4]。 食管癌在全球最常见的癌症中排名第七[5]。2018年,食管癌在中国所有癌症类型中发病率排名第五,死亡率排名第四[6]。最常见的亚型是鳞状细胞癌(SCC)和腺

微生物组在癌变和对检查点抑制的应答中的潜在作用

微生物组在癌变和对检查点抑制的应答中的潜在作用 细菌对于人体的健康和功能具有至关重要的作用,人体含有的细菌比人体细胞更多,比例为1.3:1 [1, 2]。人体内已鉴定出超过10,000种不同的微生物物种。每个人都携带10至100万亿个共生微生物细胞,这些微生物主要在肠道中。它们的基因数量超过人类基因组的基因数量,比例大致为100:1。肠道微生物组完成了许多与免疫系统的代谢和调节有关的重要任务(表)[3]。 在这里,生态失调的概念开始发挥作用,该概念是指宿主的共生微生物生态系统从健康相关的

妇科癌症中的PARP抑制:最新见解

妇科癌症中的PARP抑制:最新见解 聚(ADP-核糖)聚合酶(PARP)抑制剂已被确定为治疗晚期卵巢癌(OC)的重要药物类别,而晚期卵巢癌是女性癌症死亡的主要原因。奥拉帕尼(olaparib)和尼拉帕尼(niraparib)已被广泛批准用于对铂类化疗有应答的OC患者的维持治疗。在2019年ESMO大会上介绍的数据提供了有关在早期线中以及与其他药物类别组合使用PARP抑制的信息。此外,用维利帕尼(veliparib)进行的研究表明,该PARP抑制剂与化疗可在卵巢癌和乳腺癌中联合使用。 BA

PARP抑制剂的新应用

PARP抑制剂的新应用 转移性去势抵抗性前列腺癌 在雄激素受体(AR)靶向治疗(即恩杂鲁胺(enzalutamide)或阿比特龙(abiraterone))和紫杉烷类化疗后发生进展的转移性去势抵抗性前列腺癌(mCRPC)与预后不良相关联[1]。这些患者仅有很少的治疗选择。高达25 %的mCRPC男性在BRCA1、BRCA2、ATM或其他DNA损伤修复(DDR)基因中携带有害的种系和/或体细胞改变,包括在同源重组修复(HRR)中具有直接或间接作用的那些[2-4] 。这些改变与对PARP抑制

通过多种作用机制提高PARP抑制剂活性

通过多种作用机制提高PARP抑制剂活性 Hendrik-Tobias Arkenau,MD,PhD,FRCP,英国伦敦萨拉•坎农研究所 关于在实体瘤中使用PARP抑制剂,您从2019年ESMO大会中获得了哪些键信息? 在本年度ESMO大会上报告了若干项研究,显示使用PARP抑制剂获得了有利结果。特别是,PAOLA研究的结果可以认为是一项重大突破[1]。一线化疗后在卵巢癌患者的贝伐珠单抗维持治疗之外添加奥拉帕尼不仅在BRCA突变肿瘤患者中带来无进展生存期改善,而且在BRCA野生型患者中也

DOWNLOADS

All downloads from ESMO 2019

ESMO 2019 Solid Tumours English

Full report (english)

ESMO 2019 Solid Tumours Mandarin

Full report (mandarin)

EXPERT VIDEOS

All videointerviews from ESMO 2019

Dr. Arkenau discusses combination studies of novel PARP inhibitors with other drugs.

Dr. Lordick on the use of anti-PD-1 and other emerging therapies in gastric and oesophageal cancers.

Dr. Möhler presents novel findings on anti-PD-1 therapies and explains differences regarding the outcome of anti-PD-1 therapies in Asian and Caucasian populations.

Dr. Chowdhury talks about the use of PARP inhibitors in prostate cancer as well as the impact of pamiparib in patients with advanced solid tumors.

Over the last four years, we have reported from major conferences such as ASCO, ESMO, WCLC, ELCC or ESMO Asia on recent highlights in the field of lung cancer. Our congress reports and translations thereof into Mandarin and Japanese have received great international interest.

Alois Sillaber • Dr, Managing Director Springer-Verlag GmbH Springer Nature